Results 221 to 230 of about 242,925 (307)

Fairness perceptions in marketing strategy and across the marketing mix: An integrative review and call to action

open access: yesConsumer Psychology Review, EarlyView.
Abstract Fairness is a foundational and highly consequential construct in marketing, shaping purchase intentions, brand attitudes, complaints, boycotts, and word‐of‐mouth. Yet extant consumer research has largely concentrated on price fairness, leaving fairness across the rest of marketing strategy and the marketing mix comparatively underexplored ...
Elizabeth M. S. Friedman   +1 more
wiley   +1 more source

Conceptualizing algorithmic inequality and future agenda. An annual review of information science and technology (ARIST) paper

open access: yesJournal of the Association for Information Science and Technology, EarlyView.
Abstract The issue of inequality caused by algorithms, termed ‘algorithmic inequality’, has recently attracted scholarly attention in many disciplines due to its profound implications for society. While the body of literature on algorithmic inequality has grown, there remains a lack of comprehensive understanding of its nature, drivers, and impact ...
Shiwei Jia, Jia Tina Du, Hui Yan
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Home - About - Disclaimer - Privacy